AR105412A1 - Ultracentrifugación analítica para la caracterización de partículas virales recombinantes - Google Patents

Ultracentrifugación analítica para la caracterización de partículas virales recombinantes

Info

Publication number
AR105412A1
AR105412A1 ARP160100143A ARP160100143A AR105412A1 AR 105412 A1 AR105412 A1 AR 105412A1 AR P160100143 A ARP160100143 A AR P160100143A AR P160100143 A ARP160100143 A AR P160100143A AR 105412 A1 AR105412 A1 AR 105412A1
Authority
AR
Argentina
Prior art keywords
recombinant
recombinant viral
particles
viral particles
sedimentation
Prior art date
Application number
ARP160100143A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55305080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105412(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR105412A1 publication Critical patent/AR105412A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04Investigating sedimentation of particle suspensions
    • G01N15/042Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/405Concentrating samples by adsorption or absorption
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/4077Concentrating samples by other techniques involving separation of suspended solids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/4077Concentrating samples by other techniques involving separation of suspended solids
    • G01N2001/4083Concentrating samples by other techniques involving separation of suspended solids sedimentation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04Investigating sedimentation of particle suspensions
    • G01N15/042Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • G01N2015/045Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates by optical analysis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan aqui métodos para caracterizar preparaciones de partículas virales recombinantes usando ultracentrifugación analítica. Las partículas virales recombinantes incluyen partículas virales adeno-asociadas recombinantes, partículas adenovirales recombinantes, partículas lentivirales recombinantes y partículas de virus herpes simplex recombinantes. Se pueden identificar y cuantificar especies variantes de partículas virales recombinantes que incluyen cápsides vacías y partículas virales recombinantes con genomas variantes (v.g., genomas truncados, agregados, recombinantes). Los métodos se pueden usar para caracterizar preparaciones de partículas virales recombinantes independientemente de la secuencia del genoma viral recombinante o el serotipo de la cápside viral recombinante. Reivindicación 1: Un método para caracterizar una preparación de partículas virales recombinantes que comprende las etapas de a) someter la preparación a ultracentrifugación analítica en condiciones de velocidad de sedimentación del borde, en donde la sedimentación de las partículas virales recombinantes se controla a intervalos de tiempo, b) representar gráficamente el valor de la distribución de coeficientes de sedimentación diferencial (C(s)) frente al coeficiente de sedimentación en unidades Svedberg (S), y c) integrar el área bajo cada pico en la distribución C(S) para determinar la concentración relativa de cada pico, en donde cada pico representa una especie de partícula viral recombinante viral recombinante.
ARP160100143A 2015-01-20 2016-01-20 Ultracentrifugación analítica para la caracterización de partículas virales recombinantes AR105412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562105714P 2015-01-20 2015-01-20

Publications (1)

Publication Number Publication Date
AR105412A1 true AR105412A1 (es) 2017-10-04

Family

ID=55305080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100143A AR105412A1 (es) 2015-01-20 2016-01-20 Ultracentrifugación analítica para la caracterización de partículas virales recombinantes

Country Status (13)

Country Link
US (4) US10429288B2 (es)
EP (1) EP3247793A1 (es)
JP (3) JP2018505695A (es)
KR (1) KR20170104594A (es)
CN (1) CN107646052A (es)
AR (1) AR105412A1 (es)
AU (1) AU2016209471B2 (es)
CA (1) CA2974378A1 (es)
EA (1) EA201791630A1 (es)
IL (4) IL310375A (es)
TW (1) TWI745285B (es)
UY (1) UY36522A (es)
WO (1) WO2016118520A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791630A1 (ru) 2015-01-20 2018-04-30 Джензим Корпорейшн Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
EP3696534A1 (en) * 2019-02-14 2020-08-19 SmartDyeLivery GmbH Method for determining physicochemical properties of nanoscale systems (nss)
TW202142692A (zh) * 2020-01-29 2021-11-16 美商航海家醫療公司 用於生產aav顆粒之方法及系統
GB202004254D0 (en) 2020-03-24 2020-05-06 Puridify Ltd Characterization of gene therapy vectors
US20220033782A1 (en) * 2020-07-29 2022-02-03 Pall Corporation Adenovirus-associated viruses separation method
JP2024511409A (ja) 2021-03-22 2024-03-13 ジェンザイム・コーポレーション 空および完全aavキャプシドのサイズ排除クロマトグラフィー解析
JP7454883B2 (ja) * 2021-04-19 2024-03-25 国立大学法人大阪大学 分子送達用粒子を特徴づけるための方法
TWI787809B (zh) * 2021-05-07 2022-12-21 台達電子工業股份有限公司 資料預篩方法及其資料預篩裝置
WO2024025787A1 (en) * 2022-07-26 2024-02-01 Brammer Bio, Llc Analytical ultracentrifugation methods
WO2024079655A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Chromatography methods for purification of aav capsids

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001650A (en) * 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
CA2228269C (en) 1995-08-03 2008-01-08 Avigen, Inc. High efficiency helper system for aav vector production
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
WO1998035062A1 (en) * 1997-02-07 1998-08-13 Lingappa Jaisri R Multistep, atp-dependent cell-free system for the assembly of human immunodeficiency virus capsids
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
JP2003511037A (ja) * 1999-10-01 2003-03-25 ジェノボ, インコーポレイテッド AAVrep/cap遺伝子を含むアデノウイルスを使用する組換えAAVの産生
DE60117550T2 (de) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
SG157224A1 (en) 2001-11-13 2009-12-29 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP2281877A3 (en) 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
SI3067417T1 (sl) 2009-06-16 2018-11-30 Genzyme Corporation Izboljšani postopki čiščenja vektorjev rekombinantnega AAV
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
SG10201601110VA (en) 2011-02-17 2016-03-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
FR3002237B1 (fr) 2013-02-15 2017-12-15 Genethon Methodes pour la production de particules virales aav double brin
EP3230441A4 (en) * 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EA201791630A1 (ru) 2015-01-20 2018-04-30 Джензим Корпорейшн Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц

Also Published As

Publication number Publication date
EA201791630A1 (ru) 2018-04-30
IL296391B2 (en) 2024-06-01
TWI745285B (zh) 2021-11-11
EP3247793A1 (en) 2017-11-29
IL253542B (en) 2020-05-31
IL274137B2 (en) 2023-02-01
IL274137B (en) 2022-10-01
WO2016118520A1 (en) 2016-07-28
UY36522A (es) 2016-08-31
US20230288308A1 (en) 2023-09-14
US20180180525A1 (en) 2018-06-28
US10429288B2 (en) 2019-10-01
IL310375A (en) 2024-03-01
IL296391A (en) 2022-11-01
JP2018505695A (ja) 2018-03-01
US20240085301A1 (en) 2024-03-14
JP2022095863A (ja) 2022-06-28
CN107646052A (zh) 2018-01-30
IL253542A0 (en) 2017-09-28
US20240077402A1 (en) 2024-03-07
AU2016209471B2 (en) 2022-03-31
US12013326B2 (en) 2024-06-18
AU2016209471A1 (en) 2017-09-07
TW201639958A (zh) 2016-11-16
US20200225139A1 (en) 2020-07-16
JP2021000110A (ja) 2021-01-07
CA2974378A1 (en) 2016-07-28
IL274137A (en) 2020-06-30
KR20170104594A (ko) 2017-09-15
IL296391B1 (en) 2024-02-01
US11639887B2 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
AR105412A1 (es) Ultracentrifugación analítica para la caracterización de partículas virales recombinantes
MX2021013486A (es) Viriones de virus adenoasociados con capside variante y metodos para su uso.
IL312792A (en) Methods for determining the serotype and heterogeneity of a viral particle and for improving the stability of RAAV particles and of AAV capsid protein variants, and the compositions containing them
DK3464064T3 (da) Vingeluftfartøj med lodret start og landing (VTOL) med komplementære, vinklede rotorer
PH12019501130A1 (en) Viral delivery of neoantigens
ZA201905485B (en) Adeno-associated virus variant capsids and methods of use thereof
MA50335A (fr) Vaccins à acide nucléique contre des virus respiratoires
CL2018001051A1 (es) Vacunas de ácido nucleico contra el virus varicela zoster (vzv)
MX2023008067A (es) Virus vaccinia atenuados competentes para replicacion con delecion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
MA55772A (fr) Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
PH12018501047A1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG10201803081TA (en) Oncolytic adenovirus encoding a b7 protein
BR112017017037A2 (pt) liberação realçada de partículas virais para o estriado e córtex
MX2019010910A (es) Viriones de virus adenoasociados con capsides variantes y metodos para su uso.
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
MX2021014338A (es) Particulas virales modificadas y usos de estas.
Gimeno et al. Effect of diluting Marek's disease vaccines on the outcomes of Marek's disease virus infection when challenged with highly virulent Marek's disease viruses
Beşir et al. Choice of incision in penetrating cardiac injuries: Which one must we prefer: Thoracotomy or sternotomy?
AR101468A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
CL2014003146A1 (es) Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus.
DK3471766T3 (da) Rekombinante, ikke-patogene mareks sygdomsviruskonstrukter, der koder for infektiøs laryngotracheitisvirus- og infektiøs bursitis virus-antigener patentkrav
MX2020009262A (es) Vectores de parapoxvirus.
Beşir et al. Penetran kalp yaralanmalarında insizyon seçimi: Hangisini tercih etmeliyiz? Torakotomi mi sternotomi mi?

Legal Events

Date Code Title Description
FB Suspension of granting procedure